Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896562 | 0.85 | — | — | |
| SCHEMBL6972906 | 0.83 | — | — | |
| SCHEMBL3575455 | 0.83 | — | — | |
| SCHEMBL10617694 | 0.78 | PKM (0.31) | — | |
| SCHEMBL10617720 | 0.78 | KDM4E (0.30) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL3381842 | 0.78 | GAA (0.40) | L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL163866 | 0.69 | — | — | |
| SCHEMBL7974047 | 0.69 | — | — | |
| SCHEMBL8474795 | 0.67 | RECQL (0.36) | CYP1A2PDE2A | |
| SCHEMBL9481270 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111699189-A | Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith | 艾尼纳制药公司 | 2020-09-22 | — | — | CN | claimed |
| CN-111116494-A | Amide compounds containing quinazolinedione structure, preparation method and application thereof | 江苏中旗科技股份有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | claimed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| CN-1111623-A | Novel herbicidal pyrimidine derivatives, process for preparation thereof and their use as herbicide | LUCKY LTD (KR) | 1995-11-15 | — | — | CN | claimed |
| EP-0658549-A1 | Pyrimidine derivatives, process for their preparation and their use as herbicide | LUCKY LTD. (KR) | 1995-06-21 | — | — | EP | claimed |
| US-5310888-A | Calcium detection | MILES INC. (US) | 1994-05-10 | — | — | US | claimed |
| EP-0594047-A1 | Arylazo chromoionophores | Bayer Corporation (US) | 1994-04-27 | — | — | EP | claimed |
| US-4889553-A | Herbicides | SCHERING AGROCHEMICALS (GB) | 1989-12-26 | — | — | US | claimed |
| EP-0107979-B1 | NOVEL PHENYL-SUBSTITUTED SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-10-12 | — | — | EP | claimed |
| EP-0132230-B1 | PROCESS FOR THE PREPARATION OF SULFONYL UREA | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | claimed |
| EP-0246749-A2 | Triazole herbicides | AgrEvo UK Limited (GB) | 1987-11-25 | — | — | EP | claimed |
| US-4656273-A | Process for producing sulfonylureas | CIBA-GEIGY CORPORATION (US) | 1987-04-07 | — | — | US | claimed |
| EP-0132230-A2 | Process for the preparation of sulfonyl urea | CIBA-GEIGY AG (CH) | 1985-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | LMNA 1377/4885SMN1; SMN2 4046/4885L3MBTL1 3083/4885 |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | LMNA 4524/4885SMN1; SMN2 3009/4885L3MBTL1 4510/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | LMNA 1281/4885SMN1; SMN2 3925/4885L3MBTL1 3068/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | LMNA 1281/4885SMN1; SMN2 3925/4885L3MBTL1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.